CA1340597C - Vecteurs d'expression renfermant le promoteur pl et site de restriction synthetique facilitant le remplacement du site de liaison aux ribosomes; plasmides contenant les vecteurs, hotes contenant les plasmides et methodes connexes - Google Patents
Vecteurs d'expression renfermant le promoteur pl et site de restriction synthetique facilitant le remplacement du site de liaison aux ribosomes; plasmides contenant les vecteurs, hotes contenant les plasmides et methodes connexesInfo
- Publication number
- CA1340597C CA1340597C CA000488832A CA488832A CA1340597C CA 1340597 C CA1340597 C CA 1340597C CA 000488832 A CA000488832 A CA 000488832A CA 488832 A CA488832 A CA 488832A CA 1340597 C CA1340597 C CA 1340597C
- Authority
- CA
- Canada
- Prior art keywords
- plasmid
- analog
- host
- growth hormone
- production
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000013612 plasmid Substances 0.000 title claims abstract description 393
- 239000013598 vector Substances 0.000 title claims abstract description 157
- 230000027455 binding Effects 0.000 title claims abstract description 149
- 238000009739 binding Methods 0.000 title claims abstract description 149
- 210000003705 ribosome Anatomy 0.000 title claims abstract description 122
- 238000000034 method Methods 0.000 title claims abstract description 101
- 239000013604 expression vector Substances 0.000 title description 44
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 247
- 102000019197 Superoxide Dismutase Human genes 0.000 claims abstract description 238
- 108010012715 Superoxide dismutase Proteins 0.000 claims abstract description 238
- 210000004027 cell Anatomy 0.000 claims abstract description 157
- 239000012634 fragment Substances 0.000 claims abstract description 119
- 238000004519 manufacturing process Methods 0.000 claims abstract description 103
- 230000014509 gene expression Effects 0.000 claims abstract description 68
- 239000000122 growth hormone Substances 0.000 claims abstract description 43
- 108091081024 Start codon Proteins 0.000 claims abstract description 38
- 230000005030 transcription termination Effects 0.000 claims abstract description 37
- 108020004414 DNA Proteins 0.000 claims abstract description 35
- 230000010076 replication Effects 0.000 claims abstract description 32
- 108091008146 restriction endonucleases Proteins 0.000 claims abstract description 27
- 241000283690 Bos taurus Species 0.000 claims abstract description 20
- 210000000056 organ Anatomy 0.000 claims abstract description 18
- 230000004083 survival effect Effects 0.000 claims abstract description 16
- 241001515965 unidentified phage Species 0.000 claims abstract description 12
- 206010063837 Reperfusion injury Diseases 0.000 claims abstract description 9
- 102000053602 DNA Human genes 0.000 claims abstract description 7
- 102000009661 Repressor Proteins Human genes 0.000 claims abstract description 6
- 108010034634 Repressor Proteins Proteins 0.000 claims abstract description 6
- 108010006025 bovine growth hormone Proteins 0.000 claims description 209
- 241000588724 Escherichia coli Species 0.000 claims description 93
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 58
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 58
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 56
- 230000012010 growth Effects 0.000 claims description 55
- 230000001580 bacterial effect Effects 0.000 claims description 53
- 229920001184 polypeptide Polymers 0.000 claims description 48
- 210000003734 kidney Anatomy 0.000 claims description 45
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 44
- 239000004098 Tetracycline Substances 0.000 claims description 41
- 229960002180 tetracycline Drugs 0.000 claims description 41
- 229930101283 tetracycline Natural products 0.000 claims description 41
- 235000019364 tetracycline Nutrition 0.000 claims description 41
- 230000010410 reperfusion Effects 0.000 claims description 38
- 150000003522 tetracyclines Chemical class 0.000 claims description 38
- 229960000723 ampicillin Drugs 0.000 claims description 35
- 208000028867 ischemia Diseases 0.000 claims description 34
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 33
- 102000018997 Growth Hormone Human genes 0.000 claims description 30
- 108010051696 Growth Hormone Proteins 0.000 claims description 30
- 229960002685 biotin Drugs 0.000 claims description 29
- 235000020958 biotin Nutrition 0.000 claims description 29
- 239000011616 biotin Substances 0.000 claims description 29
- 230000006378 damage Effects 0.000 claims description 24
- 108010079058 casein hydrolysate Proteins 0.000 claims description 22
- 208000027418 Wounds and injury Diseases 0.000 claims description 21
- 208000014674 injury Diseases 0.000 claims description 20
- 108020004999 messenger RNA Proteins 0.000 claims description 17
- 230000001965 increasing effect Effects 0.000 claims description 14
- 238000002054 transplantation Methods 0.000 claims description 12
- 108091034117 Oligonucleotide Proteins 0.000 claims description 11
- 239000005556 hormone Substances 0.000 claims description 9
- 229940088597 hormone Drugs 0.000 claims description 9
- 206010061216 Infarction Diseases 0.000 claims description 8
- 101710141454 Nucleoprotein Proteins 0.000 claims description 8
- 230000007574 infarction Effects 0.000 claims description 8
- 230000002101 lytic effect Effects 0.000 claims description 8
- 210000004087 cornea Anatomy 0.000 claims description 7
- 230000010412 perfusion Effects 0.000 claims description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 5
- 235000013336 milk Nutrition 0.000 claims description 5
- 239000008267 milk Substances 0.000 claims description 5
- 210000004080 milk Anatomy 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 206010059866 Drug resistance Diseases 0.000 claims description 3
- 208000036982 Spinal cord ischaemia Diseases 0.000 claims description 3
- 238000009877 rendering Methods 0.000 claims description 3
- 101100446506 Mus musculus Fgf3 gene Proteins 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 101150025129 POP1 gene Proteins 0.000 claims 1
- 239000000376 reactant Substances 0.000 claims 1
- 238000003780 insertion Methods 0.000 abstract description 25
- 230000037431 insertion Effects 0.000 abstract description 25
- 239000013587 production medium Substances 0.000 abstract description 23
- 101000771674 Homo sapiens Apolipoprotein E Proteins 0.000 abstract description 20
- 102000053020 human ApoE Human genes 0.000 abstract description 19
- 230000009467 reduction Effects 0.000 abstract description 17
- 230000001976 improved effect Effects 0.000 abstract description 10
- 241000287828 Gallus gallus Species 0.000 abstract description 6
- 231100000878 neurological injury Toxicity 0.000 abstract description 2
- 238000010276 construction Methods 0.000 description 96
- 102000004169 proteins and genes Human genes 0.000 description 92
- 235000018102 proteins Nutrition 0.000 description 89
- 239000000243 solution Substances 0.000 description 82
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 77
- 230000006698 induction Effects 0.000 description 69
- 239000002609 medium Substances 0.000 description 64
- 150000001413 amino acids Chemical class 0.000 description 55
- 239000002054 inoculum Substances 0.000 description 55
- 235000002639 sodium chloride Nutrition 0.000 description 50
- 241000894006 Bacteria Species 0.000 description 44
- 239000011780 sodium chloride Substances 0.000 description 39
- 229940024606 amino acid Drugs 0.000 description 38
- 235000001014 amino acid Nutrition 0.000 description 38
- 101000824878 Gallus gallus Somatotropin Proteins 0.000 description 35
- 102000004594 DNA Polymerase I Human genes 0.000 description 34
- 108010017826 DNA Polymerase I Proteins 0.000 description 34
- 230000000694 effects Effects 0.000 description 34
- 239000000499 gel Substances 0.000 description 31
- 210000002216 heart Anatomy 0.000 description 31
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 30
- 229940023064 escherichia coli Drugs 0.000 description 29
- 239000002299 complementary DNA Substances 0.000 description 28
- 229930182817 methionine Natural products 0.000 description 28
- 235000006109 methionine Nutrition 0.000 description 28
- 229960004452 methionine Drugs 0.000 description 28
- 230000009466 transformation Effects 0.000 description 28
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 27
- 239000001301 oxygen Substances 0.000 description 27
- 229910052760 oxygen Inorganic materials 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 25
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 24
- 239000000872 buffer Substances 0.000 description 24
- 230000035897 transcription Effects 0.000 description 24
- 238000013518 transcription Methods 0.000 description 24
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 23
- 238000005119 centrifugation Methods 0.000 description 23
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 23
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 22
- 239000008103 glucose Substances 0.000 description 22
- 238000012360 testing method Methods 0.000 description 20
- 238000000108 ultra-filtration Methods 0.000 description 20
- 239000000203 mixture Substances 0.000 description 19
- 150000003254 radicals Chemical class 0.000 description 18
- 239000011573 trace mineral Substances 0.000 description 18
- 235000013619 trace mineral Nutrition 0.000 description 18
- 241000283973 Oryctolagus cuniculus Species 0.000 description 17
- 238000005273 aeration Methods 0.000 description 17
- 230000008901 benefit Effects 0.000 description 17
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 17
- 230000000302 ischemic effect Effects 0.000 description 17
- 238000011084 recovery Methods 0.000 description 17
- 239000006228 supernatant Substances 0.000 description 17
- 239000000725 suspension Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 16
- JQECLVNLAZGHRQ-CIUDSAMLSA-N Met-Asp-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(N)=O JQECLVNLAZGHRQ-CIUDSAMLSA-N 0.000 description 16
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 16
- 229940041514 candida albicans extract Drugs 0.000 description 16
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 16
- 239000012595 freezing medium Substances 0.000 description 16
- 229920002401 polyacrylamide Polymers 0.000 description 16
- 238000006722 reduction reaction Methods 0.000 description 16
- 239000012465 retentate Substances 0.000 description 16
- 230000014616 translation Effects 0.000 description 16
- 239000012138 yeast extract Substances 0.000 description 16
- 239000006137 Luria-Bertani broth Substances 0.000 description 15
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 15
- UDPGUMQDCGORJQ-UHFFFAOYSA-N (2-chloroethyl)phosphonic acid Chemical compound OP(O)(=O)CCCl UDPGUMQDCGORJQ-UHFFFAOYSA-N 0.000 description 14
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 14
- 229920002684 Sepharose Polymers 0.000 description 14
- 239000010949 copper Substances 0.000 description 14
- 238000004690 coupled electron pair approximation Methods 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- 108010000521 Human Growth Hormone Proteins 0.000 description 13
- -1 Superoxide radicals Chemical class 0.000 description 13
- 239000012064 sodium phosphate buffer Substances 0.000 description 13
- 239000011701 zinc Substances 0.000 description 13
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 12
- 239000000854 Human Growth Hormone Substances 0.000 description 12
- 102000002265 Human Growth Hormone Human genes 0.000 description 12
- HGCNKOLVKRAVHD-UHFFFAOYSA-N L-Met-L-Phe Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 HGCNKOLVKRAVHD-UHFFFAOYSA-N 0.000 description 12
- HGCNKOLVKRAVHD-RYUDHWBXSA-N Met-Phe Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 HGCNKOLVKRAVHD-RYUDHWBXSA-N 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 12
- 108010068488 methionylphenylalanine Proteins 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 12
- 239000012460 protein solution Substances 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 230000029087 digestion Effects 0.000 description 11
- 239000012153 distilled water Substances 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 238000004321 preservation Methods 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 238000000855 fermentation Methods 0.000 description 10
- 230000004151 fermentation Effects 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 238000013519 translation Methods 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 241000282472 Canis lupus familiaris Species 0.000 description 9
- 108010076119 Caseins Proteins 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 9
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 9
- 229910017518 Cu Zn Inorganic materials 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 9
- 238000013019 agitation Methods 0.000 description 9
- 239000005018 casein Substances 0.000 description 9
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 9
- 235000021240 caseins Nutrition 0.000 description 9
- 239000000306 component Substances 0.000 description 9
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 230000036961 partial effect Effects 0.000 description 9
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 8
- 102000016938 Catalase Human genes 0.000 description 8
- 108010053835 Catalase Proteins 0.000 description 8
- 229910017752 Cu-Zn Inorganic materials 0.000 description 8
- 229910017943 Cu—Zn Inorganic materials 0.000 description 8
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 8
- 241000282887 Suidae Species 0.000 description 8
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 8
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- TVZPLCNGKSPOJA-UHFFFAOYSA-N copper zinc Chemical compound [Cu].[Zn] TVZPLCNGKSPOJA-UHFFFAOYSA-N 0.000 description 8
- 229940109239 creatinine Drugs 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000011081 inoculation Methods 0.000 description 8
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 238000012261 overproduction Methods 0.000 description 8
- 230000000644 propagated effect Effects 0.000 description 8
- 229960003495 thiamine Drugs 0.000 description 8
- 235000019157 thiamine Nutrition 0.000 description 8
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 8
- 239000011721 thiamine Substances 0.000 description 8
- 229940088174 thiamine 1 mg Drugs 0.000 description 8
- 101150037123 APOE gene Proteins 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 239000006151 minimal media Substances 0.000 description 7
- 229950007002 phosphocreatine Drugs 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000004224 protection Effects 0.000 description 7
- 238000003127 radioimmunoassay Methods 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 239000007974 sodium acetate buffer Substances 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- 238000011144 upstream manufacturing Methods 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 6
- 235000004279 alanine Nutrition 0.000 description 6
- 239000004202 carbamide Substances 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- 230000001276 controlling effect Effects 0.000 description 6
- 229910052802 copper Inorganic materials 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 238000005187 foaming Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
- 239000002516 radical scavenger Substances 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 239000001632 sodium acetate Substances 0.000 description 6
- 235000017281 sodium acetate Nutrition 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000002303 tibia Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 102000008128 Apolipoprotein E3 Human genes 0.000 description 5
- 108010060215 Apolipoprotein E3 Proteins 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 5
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 5
- 108020004511 Recombinant DNA Proteins 0.000 description 5
- 238000012300 Sequence Analysis Methods 0.000 description 5
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 5
- 239000011543 agarose gel Substances 0.000 description 5
- 150000001450 anions Chemical class 0.000 description 5
- 210000000709 aorta Anatomy 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000008366 buffered solution Substances 0.000 description 5
- 239000001110 calcium chloride Substances 0.000 description 5
- 229910001628 calcium chloride Inorganic materials 0.000 description 5
- 235000011148 calcium chloride Nutrition 0.000 description 5
- 230000006037 cell lysis Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 230000002440 hepatic effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000004255 ion exchange chromatography Methods 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 238000001155 isoelectric focusing Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000000159 protein binding assay Methods 0.000 description 5
- 230000017854 proteolysis Effects 0.000 description 5
- 101150017120 sod gene Proteins 0.000 description 5
- 239000001488 sodium phosphate Substances 0.000 description 5
- 229960003339 sodium phosphate Drugs 0.000 description 5
- 229910000162 sodium phosphate Inorganic materials 0.000 description 5
- 235000011008 sodium phosphates Nutrition 0.000 description 5
- 230000006641 stabilisation Effects 0.000 description 5
- 238000011105 stabilization Methods 0.000 description 5
- 229940032362 superoxide dismutase Drugs 0.000 description 5
- 230000014621 translational initiation Effects 0.000 description 5
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 5
- 230000002861 ventricular Effects 0.000 description 5
- 229910052725 zinc Inorganic materials 0.000 description 5
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 4
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 4
- 239000012506 Sephacryl® Substances 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 4
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 4
- 229960005305 adenosine Drugs 0.000 description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 230000035487 diastolic blood pressure Effects 0.000 description 4
- 229930182830 galactose Natural products 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 230000006651 lactation Effects 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 230000001817 pituitary effect Effects 0.000 description 4
- 230000002028 premature Effects 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 238000001243 protein synthesis Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000002463 transducing effect Effects 0.000 description 4
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 3
- 102000018616 Apolipoproteins B Human genes 0.000 description 3
- 108010027006 Apolipoproteins B Proteins 0.000 description 3
- 208000035404 Autolysis Diseases 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 206010057248 Cell death Diseases 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 108010075031 Cytochromes c Proteins 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 206010011878 Deafness Diseases 0.000 description 3
- 241000701959 Escherichia virus Lambda Species 0.000 description 3
- 229940123457 Free radical scavenger Drugs 0.000 description 3
- 206010062767 Hypophysitis Diseases 0.000 description 3
- 229920006063 Lamide® Polymers 0.000 description 3
- 102000001851 Low Density Lipoprotein Receptor-Related Protein-1 Human genes 0.000 description 3
- 108010015340 Low Density Lipoprotein Receptor-Related Protein-1 Proteins 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 108010063312 Metalloproteins Proteins 0.000 description 3
- 102000010750 Metalloproteins Human genes 0.000 description 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 210000002376 aorta thoracic Anatomy 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 230000007541 cellular toxicity Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 230000001609 comparable effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 3
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000000763 evoking effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 210000004349 growth plate Anatomy 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000007154 intracellular accumulation Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 229960001855 mannitol Drugs 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229960003151 mercaptamine Drugs 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 235000021590 normal diet Nutrition 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 239000000082 organ preservation Substances 0.000 description 3
- 108010070915 orgotein Proteins 0.000 description 3
- 229960004534 orgotein Drugs 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 230000001292 preischemic effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000700 radioactive tracer Substances 0.000 description 3
- 210000002254 renal artery Anatomy 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000028043 self proteolysis Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(I) nitrate Inorganic materials [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- TUGDLVFMIQZYPA-UHFFFAOYSA-N tetracopper;tetrazinc Chemical compound [Cu+2].[Cu+2].[Cu+2].[Cu+2].[Zn+2].[Zn+2].[Zn+2].[Zn+2] TUGDLVFMIQZYPA-UHFFFAOYSA-N 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 210000001364 upper extremity Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- 241000014654 Adna Species 0.000 description 2
- 108010039627 Aprotinin Proteins 0.000 description 2
- 108010077805 Bacterial Proteins Proteins 0.000 description 2
- 101710125089 Bindin Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 229920002271 DEAE-Sepharose Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 102000002278 Ribosomal Proteins Human genes 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- 208000000223 Solitary Kidney Diseases 0.000 description 2
- 101150080168 XA21 gene Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- 230000003872 anastomosis Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000003111 growth hormone derivative Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000013029 homogenous suspension Substances 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 230000002631 hypothermal effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 238000011587 new zealand white rabbit Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229940070376 protein Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229960001407 sodium bicarbonate Drugs 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 210000003270 subclavian artery Anatomy 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000011426 transformation method Methods 0.000 description 2
- 229940108519 trasylol Drugs 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 description 2
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical compound NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 101150096316 5 gene Proteins 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 102000011399 Anion exchange proteins Human genes 0.000 description 1
- 108050001632 Anion exchange proteins Proteins 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 108010006591 Apoenzymes Proteins 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102000006410 Apoproteins Human genes 0.000 description 1
- 108010083590 Apoproteins Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000132092 Aster Species 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000237074 Centris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 102100027186 Extracellular superoxide dismutase [Cu-Zn] Human genes 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 240000004260 Garcinia hombroniana Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101000836222 Homo sapiens Extracellular superoxide dismutase [Cu-Zn] Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 102000011965 Lipoprotein Receptors Human genes 0.000 description 1
- 108010061306 Lipoprotein Receptors Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 101150084044 P gene Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 241000702058 Phage 21 Species 0.000 description 1
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102100026827 Protein associated with UVRAG as autophagy enhancer Human genes 0.000 description 1
- 101710102978 Protein associated with UVRAG as autophagy enhancer Proteins 0.000 description 1
- 101100520501 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) pmpR gene Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- XDXHAEQXIBQUEZ-UHFFFAOYSA-N Ropinirole hydrochloride Chemical compound Cl.CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 XDXHAEQXIBQUEZ-UHFFFAOYSA-N 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 241000219289 Silene Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 101710185500 Small t antigen Proteins 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- 229960005054 acepromazine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000007621 bhi medium Substances 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000001451 cardiotoxic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 210000000399 corneal endothelial cell Anatomy 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000002298 density-gradient ultracentrifugation Methods 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000007323 disproportionation reaction Methods 0.000 description 1
- 230000001083 documented effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 108091005645 formylated proteins Proteins 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 230000001227 hypertriglyceridemic effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000012332 laboratory investigation Methods 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 230000036722 left ventricular developed pressure Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000008604 lipoprotein metabolism Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000001320 lysogenic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000009854 mucosal lesion Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000001225 nuclear magnetic resonance method Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000016021 phenotype Diseases 0.000 description 1
- 229960003418 phenoxybenzamine Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 108700022487 rRNA Genes Proteins 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000037974 severe injury Diseases 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000003238 somatosensory effect Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000002311 subsequent effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000002972 tibial nerve Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C12N15/69—Increasing the copy number of the vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- C12N15/73—Expression systems using phage (lambda) regulatory sequences
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/449,125 US5162217A (en) | 1984-08-27 | 1989-12-08 | Plasmids for expression of human superoxide dismutase (SOD) analogs containing lambda PL promoter with engineered restriction site for substituting ribosomal binding sites and methods of use thereof |
| CA000616018A CA1340464C (fr) | 1984-08-27 | 1991-03-01 | Methode de production de superoxyde-dismutase dans une cellule bacterienne |
| US07/933,500 US5455029A (en) | 1984-08-27 | 1992-08-21 | Therapeutic compositions comprising a mixture of human CuZn superoxide dismutase analogs |
| US07/933,682 US5457042A (en) | 1984-08-27 | 1992-08-21 | Sod polypeptide analogs |
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64455184A | 1984-08-27 | 1984-08-27 | |
| US64424584A | 1984-08-27 | 1984-08-27 | |
| US64467184A | 1984-08-27 | 1984-08-27 | |
| US64511984A | 1984-08-27 | 1984-08-27 | |
| US644,105 | 1984-08-27 | ||
| US644,671 | 1984-08-27 | ||
| US645,119 | 1984-08-27 | ||
| US644,245 | 1984-08-27 | ||
| US06/644,105 US4742004A (en) | 1984-08-27 | 1984-08-27 | Method for producing enzymatically active eucaryotic sod in bacteria |
| US644,551 | 1984-08-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1340597C true CA1340597C (fr) | 1999-06-22 |
Family
ID=27542038
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000488832A Expired - Lifetime CA1340597C (fr) | 1984-08-27 | 1985-08-15 | Vecteurs d'expression renfermant le promoteur pl et site de restriction synthetique facilitant le remplacement du site de liaison aux ribosomes; plasmides contenant les vecteurs, hotes contenant les plasmides et methodes connexes |
| CA000616018A Expired - Lifetime CA1340464C (fr) | 1984-08-27 | 1991-03-01 | Methode de production de superoxyde-dismutase dans une cellule bacterienne |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000616018A Expired - Lifetime CA1340464C (fr) | 1984-08-27 | 1991-03-01 | Methode de production de superoxyde-dismutase dans une cellule bacterienne |
Country Status (15)
| Country | Link |
|---|---|
| EP (2) | EP0173280B1 (fr) |
| JP (4) | JP2933280B2 (fr) |
| AT (2) | ATE184916T1 (fr) |
| AU (1) | AU603331B2 (fr) |
| CA (2) | CA1340597C (fr) |
| DE (2) | DE3586473T2 (fr) |
| DK (1) | DK384185A (fr) |
| GR (1) | GR852030B (fr) |
| HK (1) | HK151695A (fr) |
| HU (2) | HU215160B (fr) |
| IE (1) | IE61141B1 (fr) |
| IL (3) | IL76192A (fr) |
| MY (1) | MY130321A (fr) |
| NZ (1) | NZ213154A (fr) |
| PT (1) | PT81025B (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL71689A0 (en) * | 1983-04-29 | 1984-07-31 | Yeda Res & Dev | Human superoxide dismutase production |
| BG49718A3 (en) * | 1983-07-15 | 1992-01-15 | Bio- Technology General Corp | Method for preparing of polypeptid with superoxiddismutasne activitty |
| EP0340805B1 (fr) * | 1983-10-03 | 1997-07-16 | Chiron Corporation | Superoxyde dismutase et son expression dans les microorganismes |
| CA1267615A (fr) * | 1984-08-27 | 1990-04-10 | Dan Hadary | Methode pour la recuperation d'hormones de croissance purifiees a patir de microorganismes modifies par des techniques de genie genetique |
| JP2594535B2 (ja) * | 1984-11-30 | 1997-03-26 | サントリー株式会社 | 高発現ベクターおよびその利用 |
| US5037806A (en) * | 1985-02-22 | 1991-08-06 | Monsanto Company | Biologically active method using somatotropins |
| EP0239631A4 (fr) * | 1985-10-04 | 1989-01-12 | Biotech Res Partners Ltd | Apolipoproteines recombinantes et procedes. |
| GB8701848D0 (en) * | 1987-01-28 | 1987-03-04 | Celltech Ltd | Polypeptides |
| IL96136A (en) * | 1989-11-07 | 2000-12-06 | Bio Technology General Corp | Use of hydrophobic chromatography in a method for purification of copper-zinc superoxide dismutase from cells containing same |
| WO1991007496A1 (fr) * | 1989-11-09 | 1991-05-30 | Allied-Signal Inc. | Clonage et expression de genes codant pour des polypeptides comprenant une ou plusieurs sequences d'acides amines se repetant |
| DE4239877C1 (de) * | 1992-11-27 | 1994-03-17 | Boehringer Ingelheim Int | Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung |
| GB9303988D0 (en) * | 1993-02-26 | 1993-04-14 | Health Lab Service Board | Bi-functional expression systems |
| US6030810A (en) | 1997-02-26 | 2000-02-29 | Delgado; Stephen Gregory | Cloned tetrodotoxin-sensitive sodium channel α-subunit and a splice variant thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK143412C (da) * | 1979-05-17 | 1982-05-24 | Forenede Bryggerier As | Fremgangsmaade til udvinding af cu,zn-superoxid-dismutase fra gaer |
| EP0041767B1 (fr) * | 1980-06-06 | 1993-03-03 | Biogen, Inc. | Vecteurs améliorés, méthodes de construction de tels vecteurs et d'expression de gènes clonés |
| US4506013A (en) * | 1980-10-03 | 1985-03-19 | Eli Lilly And Company | Stabilizing and selecting recombinant DNA host cells |
| CA1341012C (fr) * | 1982-09-27 | 2000-06-06 | Biogen, Inc. | Sequences d'adn, molecules d'adn recombinant, ainsi que des procedes de synthese de polypeptides aux proprietes analogues a l'hormone de croissance porcine |
| WO1984002918A1 (fr) * | 1983-01-21 | 1984-08-02 | Transgene Sa | NOUVEAUX VECTEURS D'EXPRESSION ET LEUR APPLICATION A LA PREPARATION D'UNE PROTEINE AYANT L'ACTIVITE DE L'ANTITRYPSINE-alpha1 HUMAINE |
| BG49718A3 (en) * | 1983-07-15 | 1992-01-15 | Bio- Technology General Corp | Method for preparing of polypeptid with superoxiddismutasne activitty |
| EP0138111B1 (fr) * | 1983-10-03 | 1991-11-21 | Chiron Corporation | Clonage de la dismutase du peroxyde et expression dans des micro-organismes |
-
1985
- 1985-08-15 CA CA000488832A patent/CA1340597C/fr not_active Expired - Lifetime
- 1985-08-20 NZ NZ213154A patent/NZ213154A/xx unknown
- 1985-08-22 GR GR852030A patent/GR852030B/el unknown
- 1985-08-23 DK DK384185A patent/DK384185A/da not_active Application Discontinuation
- 1985-08-26 DE DE8585110683T patent/DE3586473T2/de not_active Expired - Fee Related
- 1985-08-26 PT PT81025A patent/PT81025B/pt not_active IP Right Cessation
- 1985-08-26 IL IL7619285A patent/IL76192A/en not_active IP Right Cessation
- 1985-08-26 IE IE209385A patent/IE61141B1/en not_active IP Right Cessation
- 1985-08-26 EP EP85110683A patent/EP0173280B1/fr not_active Expired - Lifetime
- 1985-08-26 IL IL10897685A patent/IL108976A/en not_active IP Right Cessation
- 1985-08-26 DE DE3588216T patent/DE3588216T2/de not_active Expired - Fee Related
- 1985-08-26 AT AT92101250T patent/ATE184916T1/de not_active IP Right Cessation
- 1985-08-26 EP EP92101250A patent/EP0483113B1/fr not_active Expired - Lifetime
- 1985-08-26 IL IL11003985A patent/IL110039A/en not_active IP Right Cessation
- 1985-08-26 AT AT85110683T patent/ATE79407T1/de not_active IP Right Cessation
- 1985-08-27 AU AU46677/85A patent/AU603331B2/en not_active Ceased
- 1985-08-27 HU HU9801343A patent/HU215160B/hu not_active IP Right Cessation
- 1985-08-27 HU HU853240A patent/HU214977B/hu not_active IP Right Cessation
- 1985-08-27 JP JP60188317A patent/JP2933280B2/ja not_active Expired - Lifetime
-
1987
- 1987-10-01 MY MYPI87002785A patent/MY130321A/en unknown
-
1991
- 1991-03-01 CA CA000616018A patent/CA1340464C/fr not_active Expired - Lifetime
-
1994
- 1994-11-24 JP JP6330419A patent/JP2777074B2/ja not_active Expired - Lifetime
- 1994-11-24 JP JP6330418A patent/JP2688180B2/ja not_active Expired - Fee Related
-
1995
- 1995-09-21 HK HK151695A patent/HK151695A/xx not_active IP Right Cessation
-
1996
- 1996-04-17 JP JP8095694A patent/JPH08283296A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5457042A (en) | Sod polypeptide analogs | |
| US6030611A (en) | Therapeutic SOD compositions and uses thereof | |
| US5143836A (en) | Plasmids for expression of human superoxide dismutase (SOD) analogs containing lambda pl promoter with engineered restriction site for substituting ribosomal binding sites and methods of use thereof | |
| AU671728B2 (en) | Methods of production of analogues of human Cu/Zn superoxide dismutase | |
| EP0131843B1 (fr) | Vecteurs d'expression pour la production accrue de polypeptides, plasmides contenant ces vecteurs, hôtes contenant ces plasmides, produits manufacturés par ces vecteurs et méthodes correspondantes | |
| CA1340597C (fr) | Vecteurs d'expression renfermant le promoteur pl et site de restriction synthetique facilitant le remplacement du site de liaison aux ribosomes; plasmides contenant les vecteurs, hotes contenant les plasmides et methodes connexes | |
| JP2609449B2 (ja) | ヒトマンガンスーパーオキシドジスムターゼ▲下ｃ▼ＤＮＡ、その細菌中での発現及び酵素活性ヒトマンガンスーパーオキシドジスムターゼの回収方法 | |
| US5256546A (en) | Bacterial expression of porcine growth hormone | |
| US5637495A (en) | Plasmids for production of human growth hormone or polypeptide analog thereof, hosts containing the plasmids, products manufactured thereby, and related methods | |
| US5527691A (en) | Expression vectors containing lambdapl promoter and T1 T2 rRNA termination sequence, plasmids containing the vectors, hosts containing the plasmids and related methods | |
| US5670371A (en) | Bacterial expression of superoxide dismutase | |
| US5759816A (en) | Expression vectors containing λPL promoter and T1 T2 rRNA termination sequence plasmids containing the vectors hosts containing the plasmids and related methods | |
| US5198361A (en) | Plasmids for production of met-asp-gln bovine growth hormone, hosts containing the plasmids, products manufactured thereby and related methods | |
| US5112744A (en) | Plasmids for the production of human Cu-Zn superoxide dismutase, bacterial hosts containing the plasmids and methods for production and recovery of such superoxide dismutase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |
Effective date: 20160622 |